Imlifidase - Hansa Medical

Drug Profile

Imlifidase - Hansa Medical

Alternative Names: HMed-IdeS; IdeS; IgG-degrading enzyme of Streptococcus pyogenes; IgG-endopeptidase; Mac-1; Streptococcal cysteine proteinase

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hansa Medical AB
  • Developer Hansa Medical AB; Linkoping University; University College London
  • Class Antibacterials; Antirheumatics; Bacterial proteins; Enzymes
  • Mechanism of Action Immunoglobulin modulators; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Guillain-Barre syndrome; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Thrombotic thrombocytopenic purpura; Transplant rejection
  • Preclinical Cancer; Guillain-Barre syndrome
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 16 Feb 2018 Preclinical trials in Guillain-Barre syndrome (unspecified route)
  • 16 Feb 2018 Imlifidase - Hansa Medical receives Orphan Drug status for Guillain-Barre syndrome in USA
  • 16 Feb 2018 Hansa Medical plans a phase II trial for Guillain barre syndrome in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top